Geographical Variations in TP53 Mutational Spectrum in Ovarian Carcinomas

Annals of Human Genetics - Tập 70 Số 5 - Trang 594-604 - 2006
Agnieszka Dansonka‐Mieszkowska1, Agnieszka H. Ludwig‐Słomczyńska, Ewa Kraszewska, Jolanta Kupryjańczyk
1Department of Molecular Pathology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland

Tóm tắt

Summary

The TP53 gene mutational spectrum in human tumours shows variations related to tissue of origin, carcinogen exposure or molecular background. We have compared TP53 mutations in ovarian carcinomas from different geographical regions; this study was based on data extracted and verified from the IARC database (R10, 2005), and on our results from 127 carcinomas. In total 873 mutations were evaluated. Tumours from Japan and Korea had a higher frequency of exon 7 mutations (38%vs 25%, p = 0.011) and lower frequency of exon 8 mutations (11%vs 29%, p = 0.0003) than those from Western countries; they were particularly different from Norwegian tumours which showed the lowest proportion of exon 7 (19%, p = 0.001) and highest proportion of exon 8 (37%, p < 0.0001) mutations. There were also differences in the profile of TP53 hotspots. The third hotspot in tumours from Poland was amino acid (AA) 176 (8.2% of substitutions vs 1.7% in other countries, p < 0.001), while in tumours from the UK it was AA 220 (8.9%vs 2.3%, p < 0.001). Codon 273 was the only apparent hotspot in the Norwegian tumours, while it was rarely mutated in Polish and Asian tumours. In contrast to other data tumours from Norway presented with 273HIS codon (82% of mutations at AA 273, p = 0.002), while tumours from the UK shared the 273CYS codon (80%, p < 0.001). Further analysis of TP53 gene mutations in ovarian cancer by geography could provide greater insights.

Từ khóa


Tài liệu tham khảo

10.1093/carcin/22.1.133

Boyle P., 1996, Ovarian cancer 4, 91

Buller R. E., 2001, The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer, Clin Cancer Res, 7, 831

Casey G., 1996, DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies, Oncogene, 13, 1971

10.1016/S0304-3835(03)00337-9

Chen J. X., 1998, Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots, Cancer Res, 58, 2070

Creasman W. J., 1989, Announcement, FIGO stages, Gynecol Oncol, 1988, 125

10.1073/pnas.94.8.3893

10.1016/S0165-4608(98)00011-9

10.1002/path.857

10.1038/bjc.1995.428

10.1111/j.1349-7006.1994.tb02937.x

Greenblatt M. S., 1994, Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Res, 54, 4855

10.1016/S0168-9525(96)10043-3

Hollstein M., 1994, Database of p53 gene somatic mutations in human tumors and cell lines, Nucleic Acids Res, 22, 3551

10.1016/S0027-5107(98)00131-6

10.1016/S1383-5742(00)00015-6

10.1093/ajcp/102.5.665

10.1093/jnci/84.23.1793

10.1002/ijc.2910640111

10.1111/j.1349-7006.1992.tb02010.x

10.1006/gyno.1995.1125

Kohler M. F., 1993, Mutation and overexpression of p53 in early‐stage epithelial ovarian cancer, Obstet Gynecol, 81, 643

10.1093/jnci/85.18.1513

10.1073/pnas.90.11.4961

10.1016/0046-8177(95)90138-8

Kupryjanczyk J., 2000, Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction, Br J Cancer, 82, 579, 10.1054/bjoc.1999.0967

10.1038/sj.bjc.6600789

10.2307/3432969

10.1200/JCO.2000.18.23.3936

10.1016/0165-4608(95)00116-6

10.1016/j.ygyno.2004.01.043

10.2307/3433965

Mazars R., 1991, p53 mutations in ovarian cancer: a late event, Oncogene, 6, 1685

10.1159/000055316

Milner B. J., 1993, p53 mutation is a common genetic event in ovarian carcinoma, Cancer Res, 53, 2128

Mok C. H., 1992, Unifocal origin of advanced human epithelial ovarian cancers, Cancer Res, 52, 5119

10.1016/S0027-5107(99)00154-2

10.1111/j.1349-7006.1992.tb02717.x

10.1038/bjc.1994.472

10.1006/scbi.2001.0390

10.1002/humu.10081

10.1111/j.1048-891x.2004.014305.x

Peterson F., 1988, Annual report on the results of treatment in gynecological cancer

Rhei E., 1998, Molecular genetic characterization of BRCA1‐ and BRCA2‐linked hereditary ovarian cancers, Cancer Res, 58, 3193

Righetti S. C., 1996, A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin‐based chemotherapy in advanced ovarian carcinoma, Cancer Res, 56, 689

10.1038/sj.onc.1205563

10.1007/978-1-4757-3889-6_18

10.1006/gyno.1996.0302

10.1038/bjc.1996.626

10.1002/(SICI)1097-0142(19991001)86:7<1307::AID-CNCR28>3.0.CO;2-F

10.1016/S1071-5576(99)00002-7

Sigal A., 2000, Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome, Cancer Res, 60, 6788

Skilling J. S., 1996, An abundance of p53 null mutations in ovarian carcinoma, Oncogene, 13, 117

10.1002/(SICI)1096-9896(199702)181:2<158::AID-PATH742>3.0.CO;2-8

10.1038/bjc.1998.502

10.1002/humu.10189

10.1002/1097-0215(200002)9999:9999<::AID-IJC1124>3.0.CO;2-Q

10.1038/bjc.1996.324

Teneriello M. G., 1993, p53 and Ki‐ras gene mutations in epithelial ovarian neoplasms, Cancer Res, 53, 3103

10.1016/S0165-4608(98)00267-2

10.1016/S0016-5085(99)70562-7

10.1038/sj.bjc.6601537

10.1002/humu.20055

10.1093/carcin/18.7.1355

10.1097/00004347-199901000-00005

10.1093/jnci/86.20.1549

10.1093/jnci/87.15.1146

Thông tin
Thông tin xuất bản

Annals of Human Genetics

Tập 70 Số 5

594-604

Thông tin tác giả